secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0000950170-23-026747
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics announces FDA clearance of FT522 IND for Phase 1 trial in B-cell lymphoma
--------------------------------------------------------------------------------

- FDA allowed IND for FT522, an induced pluripotent stem cell-derived CAR NK-cell product candidate.
- Phase 1 dose-escalating trial will assess FT522 plus CD20-targeted mAb in relapsed/refractory B-cell lymphoma.
- Two regimens: with or without conditioning chemotherapy; starting dose 300M cells per dose in three-dose schedule.
- Regimen A enrollment to begin first; Regimen B will start after DLT clearance at initial dose level.
- Company presented update at 2023 Jefferies Healthcare Conference on June 7, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023026747/0000950170-23-026747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017023026747/fate-20230607.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-026747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer